Lacosamide: In partial-onset seizures

Drugs

Volumn 69, Issue 4, 2009, Pages 449-459

  Cross, Sarah A ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; HARKOSERIDE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PLACEBO; VALPROIC ACID;

AREA UNDER THE CURVE; ASTHENIA; ATAXIA; BALANCE DISORDER; BLURRED VISION; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; EPILEPTIC STATE; FATIGUE; FOCAL EPILEPSY; GAIT DISORDER; HEADACHE; HUMAN; MEMORY DISORDER; NAUSEA; NEUROPROTECTION; NONHUMAN; NYSTAGMUS; PRURITUS; REVIEW; SOMNOLENCE; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; TREMOR; VERTIGO; VOMITING;

ACETAMIDES; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; HUMANS; SEIZURES; THERAPEUTIC EQUIVALENCY;

EID: 63449105974     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969040-00005     Document Type: Review

References (36)

1. UK National Institute for Clinical Excellence. Technology appraisal guidance 76: newer drugs for epilepsy in adults [online]. Available fromURL: http://www.nice.org.uk/Guidance/ TA76 [Accessed 2007 Feb 27]
2. Ben-Menachem E, Henriksen O, Johannessen SI. Diagnosis and treatment of partial seizures. CNS Drugs 1999 Jan; 11 (1): 23-39
3. Johannessen SI, Ben-Menachem E. Management of focalonset seizures: an update on drug treatment. Drugs 2006; 66 (13): 1701-25
4. Johannessen Landmark C, Johannessen SI. Pharmacological management of epilepsy: recent advances and future prospects. Drugs 2008; 68 (14): 1925-35
5. Devinsky O. Patients with refractory seizures. N Engl JMed 1999 May 20; 340 (20): 1565-70
6. ®): summary of product characteristics [online]. Available from URL: http://www.emea.europa. eu/humandocs/PDFs/EPAR/vimpat/ H-863-PI-en.pdf [Accessed 2008 Nov 5]
7. Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc) 2008 Jan; 44 (1): 35-40
8. Doty P, Rudd GD, Stoehr T, et al. Lacosamide.Neurother 2007 Jan; 4 (1): 145-8
9. ® (lacosamide) tablets and injection: US prescribing information [online]. Available from URL: http:// www.fda.gov/cder/foi/label/2008/022253lbl.pdf [Accessed 2008 Oct 30]
10. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007 Spring; 13 (1): 21-42
11. Errington AC, Stöhr T, Heers C, et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008 Jan; 73 (1): 157-69
12. Czech T, Yang J, Csaszar E, et al. Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem Res 2004; 29 (12): 2189-96
13. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002 Sep; 51 (1-2): 31-71
14. ErringtonAC, Coyne L, Stöhr T, et al. Seeking amechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006 Jun; 50 (8): 1016-29
15. Stö hr T, Kupferberg HJ, Stables JP, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007 Apr 11; 74 (2-3): 147-54
16. Biomedical systems. Thorough QT trials [online]. Available from URL: http://www.biomedsys.com/Docs/Thorough %20QT%20Trials%201-15-07.pdf [Accessed 2009 Mar 13]
17. Horstmann R, Zisowsky J, Thomas D. Lacosamide demonstrates no potential for QTc-prolongation [abstract no. p245]. Epilepsia 2007 Oct; 48 Suppl. 7: 107
18. European Medicines Agency. Assessment report for Vimpat (lacosamide) [online]. Available from URL: http://www. emea.europa.eu/humandocs/PDFs/EPAR/ vimpat/H-863-en6. pdf [Accessed 2008 Oct 3]
19. Bialer M, Johannessen SI,Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004; 61 (1-3): 1-48
20. Cawello W, Kropeit D, Schiltmeyer B, et al. Food does not affect the pharmacokinetics of SPM 927 [abstract no. 2.342]. Epilepsia 2004; 45 Suppl. 7: 307
21. Horstmann R, Bonn R, CawelloW, et al. Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927 [abstract no. 2.174]. Epilepsia 2002; 43 Suppl. 7: 188
22. Ben-MenachemE, Biton V, JatuzisD, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adultswith partialonset seizures. Epilepsia 2007 May 23; 48 (7): 1308-17
23. Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008 Mar; 49 (3): 418-24
24. Schiltmeyer B, Cawello W, Kropeit D, et al. Pharmacokinetics of the new antiepileptic drug SPM927 in human subjects with different age and gender [abstract no. 2.361]. Epilepsia 2004; 45 Suppl. 7: 313
25. Hortsmann R, Bonn R, Cawello W, et al. SPM 927 does not interact with valproic acid and carbamazepine [abstract no. 1.271]. Epilepsia 2003; 44 Suppl. 9: 97
26. Schiltmeyer B, Thomas D, Horstmann R, et al. Lacosamide has no potential for interactionwithmetformin [abstract no. P869]. Diabet Med 2006 Dec 1; 23 Suppl. 4: 315-6
27. Thomas D, Scharfenecker U, Schiltmeyer B, et al. Low potential for drug-drug interaction of lacosamide [abstract no. 2.235]. Epilepsia 2006; 47 Suppl. 4: 200
28. Halász P, Kä lviä inen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. Epub 2009 Jan 17
29. Chung S, Sperling M, Biton V, et al. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures [abstract P02.097]. 60th Annual Meeting of the American Academy of Neurology; 2008 Apr 12-19, Chicago (IL)
30. International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy 1981; 22 (4): 489-501
31. US National Institutes of Health. Assess safety and efficacy of lacosamide in patients with partial seizures (SP774) [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Oct 8]
32. US National Institutes ofHealth. Determine safety and efficacy of long-term oral lacosamide in patients with partial seizures (SP756) [online]. Available from URL: http://www.clinical trials.gov [Accessed 2008 Oct 8]
33. US National Institutes ofHealth. To determine tolerability and efficacy of long-term oral lacosamide in patients with partial seizures (SP615) [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2008 Oct 3]
34. RosenfeldW, Fountain NB, Kaubrys G, et al. Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures [abstract no. 3.191]. Epilepsia 2007; 48 Suppl. 6: 318-9
35. BitonV, FountainN,Rosenow F, et al. Safety and tolerability of lacosamide: summary of adverse events [abstract and poster]. Eight European Congress on Epileptology; 2008 Sep 21-25; Berlin
36. Krauss G, Ben-Menachem E, Mameniskiene R, et al. Safety, tolerability, and pharmacokinetic parameters of 10-, 15- and 30-minute intravenous infusions as short-term replacement therapy in subjects with partial onset seizures [abstract no. S45.008]. 60th AnnualMeeting of theAmerican Academy of Neurology; 2008 Apr 12-19; Chicago (IL)